BAPTA-AM,126150-97-8,IC-0206573

BAPTA-AM is a well-known membrane-permeable Ca2+ chelator, to prevent cell injury by allaying the intracellular calcium overload[1].
The IC50 value of BAPTA-AM was investigated using a MTT assay. The IC50 value of BAPTA-AM was determined as 13.6 μM in the breast cancer 4T1 cell line.In order to determine the combined effects of bortezomib and BAPTA-AM,The cells were treated with various doses of bortezomib (1 nM and 10 nM) and BAPTA-AM (0.5 and 5 μM). The combination of 10 nM bortezomib + 5 μM BAPTA-AM was more effective compared with monotherapies (10 nM bortezomib or 5 μM BAPTA-AM alone)[2]
The calcium chelator BAPTA-AM was used to test the efficacy of calcium chelator treatment in iron overload-induced chondrocyte damage. BAPTA-AM significantly reduced iron levels in chondrocytes and inhibited iron overload-induced cell apoptosis and the expression of MMPs, thus providing new insights into the treatment of iron overload-induced diseases[3]
Restoring IP3R and Ca2+ homeostasis by pretreatment with BAPTA-AM could alleviate HTV-induced lung injury and inflammation. Assessment of the dose-dependent effects of BAPTA-AM revealed that 2.5mg/kg was sufficient to prevent the excessive ER Ca2+ release induced by HTV. The results were assessed by histopathology, W/D ratio, BALF protein levels, the number of infiltrating cells and the levels of the inflammatory cytokines IL-1β, IL-6 and TNF-α[4]